|David Rosen, PhD
Dr. Rosen has over 25 years of experience in the pharmaceutical, biotechnology, and medical device industries and has served on the management teams for both public and private companies for the last 15 years. His experience covers both research and development, including preclinical development, CMC, and project management. Teams he has led, managed, or participated in have covered the spectrum from discovery of novel therapeutic candidates through completion of phase 3 clinical trials in both the US and Europe. Therapeutics being developed has included small molecules, synthetic peptides, as well as recombinant proteins. Therapeutic areas have a wide array of indications including orthopedics (bone and cartilage repair), osteoporosis, ophthalmology, cardiovascular, nephrology and associated complications, diabetes, and dental indications.
Dr. Rosen began his career at Collagen Corporation, a medical device company, where he held scientific and project management positions working on orthopedic and soft tissue augmentation programs. His career continued with Celtrix Pharmaceuticals after it spun off from Collagen Corp enabling him to expand his experience in the CMC and facilities areas. At Celtrix, development programs included diabetes, would healing, and ophthalmology where he concluded as Sr. Vice President R&D. He then spent approximately 3 1/2 years at Hyseq Pharmaceuticals where, as Vice President of Operations, he had responsibilities for preclinical development, CMC, and facilities. Most recently, he was Sr. Vice President of R&D at Acologix Inc, where development programs included bone and cartilage repair, dental repair, and conditions associated with complications of renal failure (hyperphsphatemia and uremic pruritius). Dr. Rosen received his Ph.D. in biochemistry at the University of California, Riverside.
Gene Burton, PhD
Dr. Burton brings more than 22 years of biotechnology industry experience, working in various roles in biotechnology company management, including recombinant drug process and product development and as a seasoned protein chemist. Most recently, he was VP of Product Development and Process Sciences at Receptor BioLogix, Inc., a startup company in the oncology space working in the HER family system of receptors. Prior to the role at Receptor BioLogix, he spent over 17 years at Genentech, Inc. and 5 years at Bayer Corporation, primarily focused on recombinant protein purification, process design and manufacturing implementation at scale, for pre-IND, IND and BLA drug candidates. He also helped direct the purification design and small-scale production of over 50 different research proteins as well as contributing to the development of two different drug screening programs. He was instrumental in the development program of a drug candidate from its inception to completion of Phase III, acting as either project team leader, CMC team leader or its process development manager, over the course of the project’s history.
In addition to his industry experience, Dr. Burton served as an assistant professor and adjunct assistant professor at The Rockefeller University. He has had two postdoctoral experiences: at The Rockefeller with Dr. Stanford Moore, working with ribonuclease inhibitors, and at Stanford University with Dr. Eric Shooter, working with nerve growth factor. He is a member of the ASBMB, Society for Neuroscience and the AAAS, with more than 50 peer-reviewed publications and 5 patent applications or issues. Dr. Burton is a B.S. in Chemistry from Montana State University and a Ph.D. in Biochemistry from Michigan State University.
|Ian Manger, PhD
Dr. Ian Manger has over 20 years of academic and biotechnology industry experience and is currently Director of Business Development for Synbody Biotechnology, a new company focused on development of synthetic antibody technology. Prior to Synbody, he held the position of Program Director in the Center for Infectious Diseases and Biodefense at SRI International where he managed discovery and preclinical programs for countermeasure development against a spectrum of viral, bacterial and parasitic agents. Dr Manger joined SRI from its Sarnoff Corporation subsidiary where he led teams developing prototyping technologies for drug discovery, medical devices and biometrics. Prior to Sarnoff, Dr Manger was a consultant at RTK and led Applications and Business Development support at Fluidigm Corporation, including the conception, prototyping and intellectual property underlying new assays that are now commercial products (Biomark series). Dr Manger is a member of the ASM, NYAS and AAAS. He has also served on two NAS advisory panels. Dr Manger has a PhD in Biochemistry from Oxford University (UK) and did post-doctoral work at Monsanto (St Louis, MO) and Stanford University.